Moraxella spp
Order |
Pseudomonadales |
Family |
Moraxellaceae |
Genera |
Moraxella |
Spp |
22 |
6 medically important: |
|
- atlantae
- catarrhalis
- lacunata
- lincolnii
- nonliquefaciens
- osloensis |
History
- Moraxella - named for Victor Morax, swiss ophthalmologist who first discovered the genera
- Catarrhalis - from Greek “catarrh” = “to flow down”. Named for profuse discharge from eyes and nose
Etymology
Site |
Upper respiratory tract |
Risk Factors |
COPD |
Immunocompromised |
|
Diabetes |
|
Pathogenic mechanisms |
- Sticks to host cell using a trimeric autotransported adhesion (TAA) |
- Produce endotoxin
- Iron binding surface proteins |
| Clinical syndromes | - Otitis media (15-20% cases in children)
- bronchitis
- sinusitis
- laryngitis
- COPD exacerbations (~10% exacerbations).
- CAP (immunocompromised host).
Rarely invasive - bacteraemia, meningitis, septic arthritis |
Lab diagnostics
https://microbe-canvas.com/Bacteria/gram-negative-cocci/oxidase-positive-3/moraxella-catarrhalis.html - for microscopy and agar images
Microbiology
- Microscopy:
- GN cocco-bacilli, resistant to decolourisation (can appear GP)
- More coccoid: M. catarrhalis
- More rod-shaped: M. atlantae, M. lacunata, M. nonliquefaciens, M. osloensis
- Pairs or short chains. occasionally tetrads
- Culture:
- aerobic growth ideally 33-35 C
- Nutritionally fastidious, poor growth on blood agar. Improved on chocolate. No growth on MacConkey
- Colony:
- White or buff
- Convex
- “hockey puck” motility - stay intact and glide over agar when pushed with loop
- Species ID
- Biochemical tests:
- Catalase +
- Oxidase +
- Nitrase variable
- Usually beta-lactamase positive
- Tributyrin test:
- differentiates M. catarrhalis (+) from Neisseria spp. (-)
- Note, other Moraxella spp are Tributyrin + as well, so not useful to differentiate Moraxella spp.
- Important as Moraxella and Neisseria are both oxidase positive GN cocco-bacilli found in respiratory tract samples
- DNAse test:
- differentiates M. catarrhalis (+) from other Moraxella spp. (-)
- MALDI-TOF
Identification flowchart (from SMI ID 9)
Treatment (Sensitivities from EUCAST 14):